Welcome to our dedicated page for International Flavors & Fragrances news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors & Fragrances stock.
International Flavors & Fragrances Inc. (IFF) is a leading innovator in creating sensorial experiences that drive the world of flavors and fragrances. Headquartered in New York, the company partners with customers globally to develop unique products for the food, beverage, health, personal care, and household goods industries. With a strong commitment to discovery and innovation, IFF continuously explores new possibilities in both fine fragrances and beauty, as well as in beloved foods and beverages.
IFF's core businesses include the Nourish segment, which accounts for nearly half of its revenue. This segment specializes in producing flavors, texturants, and plant-based proteins, providing essential ingredients that enhance the appeal and functionality of food products. Additionally, the Health & Biosciences division, generating roughly one-fourth of the company's revenue, is renowned for its expertise in probiotics and enzymes, making significant contributions to health and wellness solutions.
The company leverages its global team of 7,300 professionals along with leading consumer insights, research and development, and creative expertise to deliver differentiated products. Their proprietary formulations and custom solutions are a testament to their innovative approach and customer-centric focus.
IFF has recently made remarkable advancements in excipient technology, presenting its comprehensive range at global events such as CPhI Japan 2024 and Vitafoods Europe 2024. These showcases highlight the company's commitment to driving pharmaceutical innovation, with notable products like METHOCEL™, ETHOCEL™, and POLYOX™ under its new controlled release platform, 'Timing is Everything'. This new platform emphasizes the importance of controlled release in pharmaceutical therapies, aiming to improve patient compliance and treatment efficacy.
IFF continues to expand its innovative offerings and partnerships, demonstrating a significant impact across various industries. The company's dedication to sustainability and precision in science and creativity positions it as a key player in transforming everyday experiences and contributing to a better world.
For more detailed information about their latest projects and developments, visit their official website at iff.com.
IFF has launched TEXSTAR™, an innovative enzymatic solution designed to enhance texture in dairy and plant-based fermented products without added stabilizers. The enzyme converts sucrose into poly- and oligosaccharides during fermentation, reducing sugar content while delivering premium texture with greater smoothness and increased shine. TEXSTAR™ can reduce texturant-related Scope 3 greenhouse gas emissions by up to 90% due to lower usage rates and can serve as a partial milk protein replacer to reduce carbon footprint. The solution addresses consumer preferences, with 53% of US consumers eating yogurt as a snack and 42% seeking thick, spoonable consistency.
IFF reported strong Q3 2024 financial results with sales of $2.93 billion, up 4% from the previous year. On a comparable basis, currency neutral sales increased 9%, driven by growth across all segments. Adjusted operating EBITDA was $568 million, improving 16% year-over-year. The company achieved notable volume recovery in every division, with Health & Biosciences and Scent delivering double-digit performances. Based on strong performance, IFF increased its full-year 2024 guidance, now expecting sales between $11.3-11.4 billion and adjusted operating EBITDA at the high end of $2.1-2.17 billion range.
IFF has appointed two new perfumers to its Paris-based fine fragrance team. Alexandra Carlin joins as Senior Fine Fragrance Perfumer, bringing experience from creating fragrances like Diptyque Kyoto and Amouage Honour Woman. Alex Lee joins as Fine Fragrance Perfumer, with a portfolio including Dolce & Gabbana's Velvet Infusion and Penhaligon's Agarbathi. Both perfumers have studied at ISIPCA and bring unique perspectives to IFF's creative collective. The appointments aim to strengthen IFF's Paris creative hub and enhance the company's artistic capabilities in perfumery.
IFF (NYSE: IFF) has announced its Board of Directors' declaration of a regular quarterly cash dividend of $0.40 per share of common stock. The dividend will be payable on January 8, 2025 to shareholders of record as of December 20, 2024. IFF operates as an industry leader in food, beverage, scent, health and biosciences, creating essential solutions through the combination of science and creativity.
IFF has presented its 2024 Science Awards to two distinguished university scientists for their contributions to food, nutrition, and health advancement. Tom Desmet, Ph.D. from Ghent University was recognized for his groundbreaking work in biocatalysis and enzyme design for carbohydrate synthesis. Yolanda Sanz, Ph.D. from IATA-CSIC was honored for her research on gut microbiome relationships with celiac disease, obesity, and stress-related disorders.
Each recipient receives a $30,000 prize. The awards continue the legacy of the Danisco Foundation, established in 1981, which IFF maintains following its merger with DuPont's Nutrition and Biosciences in 2021. Recipients are selected through a rigorous nomination process by IFF Technical Fellows and R&D leaders.
IFF is showcasing innovative food and beverage solutions at Gulfood Manufacturing 2024 in Dubai from November 5-7. Under the theme 'Make joy through science and creativity,' the company will present concepts focused on Experiential Delight, Health, and Affordability across beverages, dairy, snacks, bakery, and confectionery categories.
Key innovations include: cost-efficient dairy drinks with enhanced calcium levels, fizzy beverages with innovative flavors, reduced tomato paste solutions saving up to 30% in sauces, international fusion snacks, and cocoa reduction solutions for cookies and chocolate drinks. These developments aim to help manufacturers create products with sensory appeal and functional benefits while reducing costs.
IFF has launched OPTIMASH® F200 and OPTIMASH® AX enzyme solutions to maximize corn oil recovery at fuel ethanol plants. New in-plant data shows this combination can deliver up to 15 percent additional corn oil recovery, meeting growing demand in biodiesel, renewable diesel, and animal feed industries. IFF has also developed a proprietary oil mapping calculator to help ethanol producers optimize dosing for maximum recovery.
These solutions enable ethanol producers to sell ethanol into low-carbon intensity (low-CI) markets. The enzyme duo has been found to boost corn oil yield by 15.7 percent, from 0.89 lb/bu to 1.03 lb/bu. It also allows producers to enter low-CI markets by breaking down corn kernel fiber into glucose, resulting in a lower CI score and potentially qualifying for substantial tax credits.
IFF offers comprehensive technical support, including baseline and trial oil mapping, data analyses for custom dosing recommendations, and collaboration to reduce energy consumption through fiber dewatering.
IFF (NYSE:IFF), a leader in food, beverage, health, biosciences, and scent industries, has announced the release of its third quarter 2024 earnings results. The results will be disclosed after the market closes on Tuesday, November 5, 2024. Following this, the management team will host a live webcast on Wednesday, November 6, 2024, at 9:00 a.m. ET to discuss the results and outlook with investors.
Investors can access the live webcast and accompanying slide presentation on IFF's website at ir.iff.com. For those unable to attend the live event, a recorded version will be made available for replay. IFF describes itself as an international collective of thinkers partnering with customers to create essential solutions for a better world, combining science and creativity to develop products that the world craves.
IFF Pharma Solutions will showcase breakthrough research at AAPS 2024 PharmSci 360 in Salt Lake City, Utah, from Oct. 20-23. The company will demonstrate the critical role of excipients in drug formulation through scientific posters and presentations. Key advancements include:
- Nitrosamine risk mitigation
- Controlled-release performance
- Extrusion spheronization processibility and pellet quality
- Softgel stability
- Formulation of plant-based pharmaceutical gummies
IFF experts will present research on topics such as immediate-release solutions, controlled release matrix tablet formulations, and analytical methods for detecting nitrites in pharmaceutical excipients. The company aims to empower pharmaceutical manufacturers to develop safer, more effective formulations.
IFF Pharma Solutions is showcasing its 75-year legacy as an excipient manufacturer at CPHI 2024 in Milan, October 8-10. The company is unveiling new product launches and technologies, including:
1. Low nitrite excipient solutions for nitrosamine risk mitigation, such as Avicel® PH Low Nitrite (LN) and METHOCEL™ products.
2. Ultrapure alginate technologies for biotechnology, including NOVAMATRIX-3D™ and PRONOVA® UP CAM.
3. New foil bag-in-box packaging for POLYOX™ water-soluble resins, extending stability and supporting sustainability initiatives.
These innovations aim to address critical industry challenges and support pharmaceutical and biotech advancements.
FAQ
What is the current stock price of International Flavors & Fragrances (IFF)?
What is the market cap of International Flavors & Fragrances (IFF)?
What does International Flavors & Fragrances Inc. (IFF) do?
What are the core business segments of IFF?
Where is IFF headquartered?
How many employees does IFF have?
What are some recent innovations by IFF?
What is the significance of the 'Timing is Everything' platform?
How does IFF support the food industry?
What role does IFF play in the health sector?
Where can I find more information about IFF's products and services?
What is IFF's approach to innovation?
